Abstract
Over the last few years, the implication of the (pro)renin receptor [(P)RR] in the pathogenesis of end-organ damage has been shown through many different studies. The (P)RR plays a dual role when stimulated by renin or prorenin as it enhances both cell surface production of angiotensin and stimulates angiotensin-independent intracellular signaling cascades. Since Ichiharas group demonstrated activation of prorenin when it was bound to antibodies targeted against a specific region in the renin prosegment, they designed a complementary decapeptide to this region called the handle region to use as a potential (P)RR blocker (PRRB). The effects of systemic administration of the PRRB on the development and progression of different renal, cardiac and ocular pathologies have been observed and have thus proposed the blocker as a potential new treatment for these afflictions. Conversely, the specificity of the PRRB has been questioned as conflicting results have been reported in the literature. A recent study has described a new high affinity binding site for renin and prorenin to the (P)RR called the hinge region. Hence, although there is great promise in the (P)RR potential as a therapeutic target, still much research is required to better identify adequate blockers.
Keywords: (pro)renin receptor, (pro)renin receptor blocker, renin-angiotensin system, renal disease, ocular disease, cardiac pathology, central nervous system, transgenic animals, cAMP, fibrosis
Current Pharmaceutical Design
Title: (Pro)renin Receptor as a New Drug Target
Volume: 17 Issue: 33
Author(s): Basma A.M. Ahmed, Ondrej Seda and Julie L. Lavoie
Affiliation:
Keywords: (pro)renin receptor, (pro)renin receptor blocker, renin-angiotensin system, renal disease, ocular disease, cardiac pathology, central nervous system, transgenic animals, cAMP, fibrosis
Abstract: Over the last few years, the implication of the (pro)renin receptor [(P)RR] in the pathogenesis of end-organ damage has been shown through many different studies. The (P)RR plays a dual role when stimulated by renin or prorenin as it enhances both cell surface production of angiotensin and stimulates angiotensin-independent intracellular signaling cascades. Since Ichiharas group demonstrated activation of prorenin when it was bound to antibodies targeted against a specific region in the renin prosegment, they designed a complementary decapeptide to this region called the handle region to use as a potential (P)RR blocker (PRRB). The effects of systemic administration of the PRRB on the development and progression of different renal, cardiac and ocular pathologies have been observed and have thus proposed the blocker as a potential new treatment for these afflictions. Conversely, the specificity of the PRRB has been questioned as conflicting results have been reported in the literature. A recent study has described a new high affinity binding site for renin and prorenin to the (P)RR called the hinge region. Hence, although there is great promise in the (P)RR potential as a therapeutic target, still much research is required to better identify adequate blockers.
Export Options
About this article
Cite this article as:
A.M. Ahmed Basma, Seda Ondrej and L. Lavoie Julie, (Pro)renin Receptor as a New Drug Target, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220963
DOI https://dx.doi.org/10.2174/138161211798220963 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Proteinuria in Diabetes: an Endocrine Disease? (Guest Editor: Alessia Fornoni and Oliver Lenz)]
Current Diabetes Reviews 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Antidiabetic Effect of Spearmint in Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Megsin Gene: Its Genomic Analysis, Pathobiological Functions, and Therapeutic Perspectives
Current Genomics The Role of Endothelium in Cardiovascular Diseases: New Insights
Current Medicinal Chemistry The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Uterine EMG and Cervical LIF - Promising Technologies in Obstetrics
Current Women`s Health Reviews Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Editorial (Thematic Issue: Controversies and Current Approaches in the Diagnosis of Prediabetes and Diabetes Mellitus)
Current Diabetes Reviews The Role of Lifestyle Change in the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Sulfaphenazole and α-Naphthoflavone Attenuate the Metabolism of the Synthetic Cannabinoids JWH-018 and AM2201 Found in K2/Spice
Drug Metabolism Letters Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances
Reviews on Recent Clinical Trials Neonatal Environment and Neuroendocrine Programming of the Peripheral Respiratory Control System
Current Pediatric Reviews Anti-oxidative and Anti-microbial Activities of Purified MPN-1-1 from Persicaria nepalensis (Meisn.) Miyabe
Current Pharmaceutical Biotechnology Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued)